Abstract:Abstract Background Chronic lymphocytic leukemia (CLL) results in increased susceptibility to infections. T cell dysfunction is not associated with CLL in all patients; therefore, it is important to identify CLL patients with T cell defects. The role of B-cell lymphoma-2 (BCL-2) in CLL has been explored; however, few studies have examined its role in T cells in CLL patients. Herein, we have investigated the regulatory role of BCL-2 in T cells in the CLL tumor microenvironment. Methods The expression of BCL-2 in T cells was evaluated using flow cytometry. The regulatory roles of BCL-2 were investigated using single-cell RNA sequencing (scRNA-seq) and verified using multi-parameter flow cytometry on CD4 and CD8 T cells. The clinical features of BCL-2 expression in T cells in CLL were also explored. Results We found a significant increase in BCL-2 expression in the T cells of CLL patients ( n = 266). Single cell RNA sequencing (scRNA-seq) indicated that BCL-2 + CD4 + T cells had the gene signature of increased regulatory T cells (Treg); BCL-2 + CD8 + T cells showed the gene signature of exhausted cytotoxic T lymphocytes (CTL); and increased expression of BCL-2 was associated with T cell activation and cellular adhesion. The results from scRNA-seq were verified in peripheral T cells from 70 patients with CLL, wherein BCL-2 + CD4 + T cells were enriched with Tregs and had higher expression of interleukin-10 and transforming growth factor-β than BCL-2 − CD4 + T cells. BCL-2 expression in CD8 + T cells was associated with exhausted cells (PD-1 + Tim-3 + ) and weak expression of granzyme B and perforin. T cell–associated cytokine profiling revealed a negative association between BCL-2 + T cells and T cell activation. Decreased frequencies and recovery functions of BCL-2 + T cells were observed in CLL patients in complete remission after treatment with venetoclax. Conclusion BCL-2 expression in the T cells of CLL patients is associated with immunosuppression via promotion of Treg abundance and CTL exhaustion.

The Role of BCL11B in Regulating the Proliferation of Human Naive T Cells.

The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation

Dual role of BCL11B in T-cell malignancies

Critical roles of Bcl11b in T‐cell development and maintenance of T‐cell identity

Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms

Bcl10 can promote survival of antigen-stimulated B lymphocytes

BCL11B and the NuRD complex cooperatively guard T-cell fate and inhibit OPA1-mediated mitochondrial fusion in T cells

Function of B-Cell CLL/Lymphoma 11B in Glial Progenitor Proliferation and Oligodendrocyte Maturation

BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion

BCL11b interacts with RNA and proteins involved in RNA processing and developmental diseases

The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation

Bcl11b-A Critical Neurodevelopmental Transcription Factor-Roles in Health and Disease.

BCL6 Controls Contact-Dependent Help Delivery During Follicular T-B Cell Interactions

Bcl11b and combinatorial resolution of cell fate in the T-cell gene regulatory network

BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells

Phosphorylation of Bcl10 Negatively Regulates T-cell Receptor-Mediated NF-kappaB Activation.

The role of B-cell lymphoma/leukemia 11A (BCL11A) in the malignant progression of solid tumors

A mutant BCL11B-N440K protein interferes with BCL11A function during T lymphocyte and neuronal development

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Bcl11b, a Novel GATA3-interacting Protein, Suppresses Th1 While Limiting Th2 Cell Differentiation

Bcl11b prevents the intrathymic development of innate CD8 T cells in a cell intrinsic manner